French Register data confirm robust efficacy of axi-cel and liso-cel in early-relapsing LBCL

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

ASH 2025

Lymphoma

Prognostic value of early MRD status in LBCL patients treated with axi-cel or liso-cel

ASH 2025

Lymphoma

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

EHA 2025

Lymphoma

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

Lymphoma

Updated Insights from Matching-Adjusted Indirect Comparisons of Two CAR T-cell Therapies in Second-Line Treatment of R/R LBCL

EHA/ICML 2025

Lymphoma

Expanding the Curative Potential of CAR T-Cell Therapy

ASH 2025

Lymphoma

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Multiple Myeloma (MM)

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison

Adv Ther

Puig N, Diels J, van Sanden S, Mendes J, Burnett H, Cichewicz A, Lee S, Hernando T, Schecter JM, Lendvai N, Patel N, Sanchez-Pina JM, Rocchi S, Mina R, Corradini P, Cavo M, Miguel JS, Shune L, Khan AM, Sidana S, Leleu X, Manier S, Lipe B, Weisel K, Martinez-Lopez J

doi: 10.1007/s12325-025-03205-8

EHA 2025

Multiple Myeloma (MM)

Related content

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Prognostic value of early MRD status in LBCL patients treated with axi-cel or liso-cel

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

Updated Insights from Matching-Adjusted Indirect Comparisons of Two CAR T-cell Therapies in Second-Line Treatment of R/R LBCL

Expanding the Curative Potential of CAR T-Cell Therapy

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison

PREDATOR-MRD: Early daratumumab delays clinical progression in patients with MM experiencing MRD relapse